AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

10.850

+0.1501.40%

Volume:79.62K

Turnover:855.15K

Market Cap:542.61M

PE:14.10

High:10.850

Open:10.750

Low:10.500

Close:10.700

Loading ...

Overview Company News Filings

Clinuvel Pharmaceuticals Ltd (CLVLF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth ...

High Growth Tech Stocks To Watch In April 2025

Simply Wall St.

Clinuvel Pharmaceuticals to Buy Back Up to 1.5 Million Shares

MT Newswires Live

BRIEF-Clinuvel Pharmaceuticals Renews Share Buy-Back Program

Clinuvel Pharmaceuticals Ltd - Renews Share Buy-Back Program

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Repurchase of up to 1.5 Mln Ordinary Shares

THOMSON REUTERS

ASX Market Close: Index flirts with 8000 pts | March 26, 2025

The Market Herald

ASX Midday Sector Update: Materials Sector Soars, Healthcare Struggles

MT Newswires Live

Why Clinuvel, Orthocell, Vulcan, and Wildcat shares are storming higher

Clinuvel stroke drug shows ‘positive’ results – but some adverse effects left unclear

The Market Herald

Clinuvel Pharmaceuticals Reports Positive Study Results for Arterial Ischaemic Stroke Drug Candidate

MT Newswires Live

BRIEF-Clinuvel Pharmaceuticals Says CEO Philippe Wolgen To Take Temporary Leave

Clinuvel Pharmaceuticals' CEO to take Temporary Leave

MT Newswires Live

Clinuvel Pharmaceuticals Ltd - Lachlan Hay Appointed Acting CEO of Clinuvel

THOMSON REUTERS

High Growth Tech Stocks In Australia For March 2025

Simply Wall St.

Imugene Appoints CFO; Shares Fall 3%

MT Newswires Live

Clinuvel Pharmaceuticals Posts Higher Fiscal H1 Earnings, Revenue; Shares Up 8%

MT Newswires Live

Clinuvel Pharmaceuticals Ltd H1 Net Income AUD 14.08 Million

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership For February 2025

Simply Wall St.

3 ASX Growth Stocks With High Insider Ownership To Watch

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CUV.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":10.85,"timestamp":1744870320000,"preClose":10.7,"halted":0,"volume":79617,"delay":0,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41307998,"shares":50009750,"eps":0.769445,"marketStatus":"Not Yet Opened","change":0.15,"latestTime":"04-17 16:12:00 AEST","open":10.75,"high":10.85,"low":10.5,"amount":855154,"amplitude":0.03271,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.769445,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":10.7,"dividendRate":0.004608,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.681300081588836,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41307998,"roa":"14.22%","roe":"19.59%","lyrEps":0.7151,"volumeRatio":0.681300081588836,"shares":50009750,"dividePrice":0.05,"high":10.85,"amplitude":0.03271,"preClose":10.7,"low":10.5,"week52Low":9.755,"pbRate":"2.50","psRate":"5.96","week52High":17.652,"institutionHeld":0,"latestPrice":10.85,"eps":0.769445,"divideRate":0.004608,"volume":79617,"delay":0,"ttmEps":0.769445,"open":10.75,"prevYearClose":12.06,"prevWeekClose":10.85,"prevMonthClose":11.46,"prevQuarterClose":11.46,"fiveDayClose":10.86,"twentyDayClose":11.88,"sixtyDayClose":11.71},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529587483","title":"Clinuvel Pharmaceuticals Ltd (CLVLF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2529587483","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529587483?lang=en_us&edition=fundamental","pubTime":"2025-04-22 04:32","pubTimestamp":1745267545,"startTime":"0","endTime":"0","summary":"Sales Growth: Increased by 10.5% to $36 million.Total Revenues: Grew by 21% to $43 million.Expenses Growth: Contained to a modest 2% increase.Profit Before Tax: Rose by 48% to just under $22 million.Profit After Tax: Increased by almost 30% to $14 million.Earnings Per Share: Increased by 27% from $0.22 to $0.28 per share.Net Assets: Strengthened with a 7% increase since June last year.Cash Reserves: Rose by 8% to $198 million.GuruFocus has detected 2 Warning Signs with CLVLF.Clinuvel Pharmaceuticals Ltd  reported a 10.5% increase in sales to $36 million and a 21% rise in total revenues to $43 million.Clinuvel Pharmaceuticals Ltd  maintained a strong balance sheet with a 7% increase in net assets and an 8% rise in cash reserves to $198 million.Clinuvel Pharmaceuticals Ltd  faces competition in recruiting clinical trials for vitiligo, which may require strategic resource deployment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clinuvel-pharmaceuticals-ltd-clvlf-h1-203225350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CUV.AU","CLVLF"],"gpt_icon":0},{"id":"2527714507","title":"High Growth Tech Stocks To Watch In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527714507","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527714507?lang=en_us&edition=fundamental","pubTime":"2025-04-15 03:35","pubTimestamp":1744659336,"startTime":"0","endTime":"0","summary":"The Australian market showed strength on Monday, with the IT sector leading gains by 2.6%, buoyed by positive momentum from Wall Street and a rise in materials driven by higher iron ore and gold prices. In this environment, identifying high growth tech stocks involves looking for companies that are capitalizing on current market trends and demonstrating resilience during earnings season, as they can potentially offer significant opportunities for investors seeking exposure to innovative sectors.Click here to see the full list of 48 stocks from our ASX High Growth Tech and AI Stocks screener.Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally; it has a market cap of A$536.43 million.Operations: Clinuvel Pharmaceuticals generates revenue primarily from its biopharmaceutical sector, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-193536682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7508","CUV.AU","XAO.AU","SDR.AU","BK7067","IFM.AU","BK7016","BK7503","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2522235477","title":"Clinuvel Pharmaceuticals to Buy Back Up to 1.5 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2522235477","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522235477?lang=en_us&edition=fundamental","pubTime":"2025-03-27 06:30","pubTimestamp":1743028235,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said it will repurchase a maximum of 1.5 million ordinary fully-paid shares as part of an on-market buyback, according to a Thursday Australian bourse filing.The repurchases are expected to start on April 10 and will run for 12 months, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XJO.AU","CUV.AU","XKO.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2522351474","title":"BRIEF-Clinuvel Pharmaceuticals Renews Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522351474","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522351474?lang=en_us&edition=fundamental","pubTime":"2025-03-27 06:04","pubTimestamp":1743026647,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Renews Share Buy-Back ProgramMarch 27 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:RENEWS SHARE BUY-BACK PROGRAMREPURCHASE OF UP TO 1.5 MILLION ORDINARY SHARESFurther company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2522735111","title":"Clinuvel Pharmaceuticals Ltd - Renews Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522735111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522735111?lang=en_us&edition=fundamental","pubTime":"2025-03-27 06:03","pubTimestamp":1743026594,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2522351114","title":"Clinuvel Pharmaceuticals Ltd -  Repurchase of up to 1.5 Mln Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2522351114","media":"THOMSON REUTERS","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522351114?lang=en_us&edition=fundamental","pubTime":"2025-03-27 06:03","pubTimestamp":1743026594,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90ZR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2522124298","title":"ASX Market Close: Index flirts with 8000 pts | March 26, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522124298","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522124298?lang=en_us&edition=fundamental","pubTime":"2025-03-26 14:44","pubTimestamp":1742971440,"startTime":"0","endTime":"0","summary":"The ASX closed up 0.7% at 7,999 points.Staples was the best performing sector, up 1.2%, followed by Real Estate, Industrials and Financials, all up around 1.1%.Health Care was the sole sector in the red, down 0.5%.Frontier Energyclosed up 14.8% after progressing to the second stage of its strategic investor process for the Waroona Renewable Energy Project following multiple non-binding indicative offers from potential investors.Delta Lithiumfinished up 2.9% after an update on exploration and permitting at its 100%-owned Mt Ida Gold Project in WesternAustralia’s Eastern Goldfields.Paladin Energy  has wrapped up down 11.6%. Investors have been selling the stock following a not-so-positiveupdateon the Langer Heinrich Mine in Namibia.Sovereign Metals  closed down 16.4% following the completion of an institutional placement today.Lunnon Metalsclosed down 4.3% after completing key mining and exploration surveys in collaboration with the Ngadju People, the traditional owners of the land encom","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-flirts-with-8000-pts-march-26-2025-2025-03-26/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7083","PDN.AU","DLI.AU","BK7060","BK7509","SVM.AU","LM8.AU","BK7067","BK7095","BK7506","CUV.AU","FHE.AU","BK7508"],"gpt_icon":0},{"id":"2522863969","title":"ASX Midday Sector Update: Materials Sector Soars, Healthcare Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2522863969","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522863969?lang=en_us&edition=fundamental","pubTime":"2025-03-26 10:29","pubTimestamp":1742956181,"startTime":"0","endTime":"0","summary":"Materials stocks jumped 1.24% at midday Wednesday, leading a broad-based rally on the ASX. Australia's consumer price index rose 2.4% in the 12 months to February, following a 2.5% increase in the yea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","HCSG","ARKG","BK4585","BK7095","BK4588","BK4137","CUV.AU","BK7067","BK7508","EMH.AU","XKO.AU","XJO.AU","BK7504","BK4544"],"gpt_icon":1},{"id":"2522989091","title":"Why Clinuvel, Orthocell, Vulcan, and Wildcat shares are storming higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2522989091","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522989091?lang=en_us&edition=fundamental","pubTime":"2025-03-26 09:58","pubTimestamp":1742954294,"startTime":"0","endTime":"0","summary":"In afternoon tradeS&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.8% to 8,004.2 points. Four ASX shares that are rising more than","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/26/why-clinuvel-orthocell-vulcan-and-wildcat-shares-are-storming-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["AIS","AIS.AU","WC8.AU","PLS.AU","BK7508","BK7067","BK7110","OCC.AU","BK7507","BK7506","XJO.AU","CUV.AU","VUL.AU","BK7095","BK7504"],"gpt_icon":0},{"id":"2522650198","title":"Clinuvel stroke drug shows ‘positive’ results – but some adverse effects left unclear","url":"https://stock-news.laohu8.com/highlight/detail?id=2522650198","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522650198?lang=en_us&edition=fundamental","pubTime":"2025-03-26 09:53","pubTimestamp":1742953980,"startTime":"0","endTime":"0","summary":"Clinuvel  shares have jumped on Tuesday morning on higher than average volumes as the health care company reported a clinical trial win with its stroke drug, ‘PRENUMBRA’ – chemical name afamelanotide.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.Shares jumped over 2% in Wednesday morning trades in what will be taken as relief by some shareholders given the stock’s declines across the last twelve months.“With the CUV801 and CUV803 studies we have generated a small, but encouraging, data set that demonstrates the drug’s safety profile in patients with strokes of varying degrees of severity, as well as first indications that patients may benefit from treatment,” Clinuvel Chair Prof. Jeffrey Rosenfeld said.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/clinuvel-stroke-drug-shows-positive-results-but-some-adverse-effects-left-unclear-2025-03-26/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2522853345","title":"Clinuvel Pharmaceuticals Reports Positive Study Results for Arterial Ischaemic Stroke Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853345","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853345?lang=en_us&edition=fundamental","pubTime":"2025-03-26 08:20","pubTimestamp":1742948413,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said preliminary results from its second clinical study investigating its afamelanotide drug candidate as a treatment for arterial ischaemic stroke were positive, ac","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2520632719","title":"BRIEF-Clinuvel Pharmaceuticals Says CEO Philippe Wolgen To Take Temporary Leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2520632719","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520632719?lang=en_us&edition=fundamental","pubTime":"2025-03-18 09:21","pubTimestamp":1742260873,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Says CEO Philippe Wolgen To Take Temporary LeaveMarch 18 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:CEO PHILIPPE WOLGEN TO TAKE TEMPORARY LEAVELACHLAN HAY APPOINTED ACTING CEO OF CLINUVELFurther company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q00JA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2520680808","title":"Clinuvel Pharmaceuticals' CEO to take Temporary Leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2520680808","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520680808?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:50","pubTimestamp":1742251809,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  Chief Executive Philippe Wolgen will be on a temporary leave of absence from his full duties due to health reasons, according to a Tuesday filing with the Australian bourse.During Wolgen's absence, Chief Operations Officer Lachlan Hay will serve as acting CEO, with the executive team handling Wolgen's daily responsibilities for up to three months, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2520722684","title":"Clinuvel Pharmaceuticals Ltd - Lachlan Hay Appointed Acting CEO of Clinuvel","url":"https://stock-news.laohu8.com/highlight/detail?id=2520722684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520722684?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:02","pubTimestamp":1742248950,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00JA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2520967554","title":"High Growth Tech Stocks In Australia For March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520967554","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520967554?lang=en_us&edition=fundamental","pubTime":"2025-03-17 03:05","pubTimestamp":1742151929,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a turbulent period marked by global trade tensions and fluctuating indices, investors are keeping a keen eye on high-growth tech stocks that have the potential to thrive amid economic uncertainties. In this environment, identifying promising tech companies involves looking for those with innovative solutions and strong adaptability to shifting market dynamics, making them well-positioned to capitalize on emerging opportunities.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/high-growth-tech-stocks-in-australia-for-march-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7016","XKO.AU","BK7508","XJO.AU","BK7503","XAO.AU","IFM.AU","CUV.AU","BK7067","SDR.AU"],"gpt_icon":0},{"id":"2516660815","title":"Imugene Appoints CFO; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516660815","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516660815?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:35","pubTimestamp":1741044931,"startTime":"0","endTime":"0","summary":"Imugene  appointed Clinuvel Pharmaceuticals'  former Chief Financial Officer Darren Keamy as CFO, effective immediately, according to a Tuesday filing with the Australian bourse.Keamy will succeed current CFO Mike Tonroe, the filing said.Shares of the pharmaceutical company fell 3% in recent trade,Price : $0.04, Change: $-0.00100, Percent Change: -2.78%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","XJO.AU","XAO.AU","CUV.AU","BK7508","XKO.AU","IMU.AU"],"gpt_icon":0},{"id":"2514890322","title":"Clinuvel Pharmaceuticals Posts Higher Fiscal H1 Earnings, Revenue; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514890322","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514890322?lang=en_us&edition=fundamental","pubTime":"2025-02-27 08:29","pubTimestamp":1740616182,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  reported Thursday that its earnings per diluted share in the fiscal first half rose to AU$0.28 from AU$0.212 a year earlier.Analysts polled by Visible Alpha were expecting an EPS of AU$0.20.Revenue for the six months ended Dec. 31, 2024, was AU$35.6 million, up from AU$32.3 million in the same period a year earlier. Analysts surveyed by Visible Alpha expected AU$35.6 million.The company's shares rose past 8% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU"],"gpt_icon":0},{"id":"2514894068","title":"Clinuvel Pharmaceuticals Ltd H1 Net Income AUD 14.08 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514894068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514894068?lang=en_us&edition=fundamental","pubTime":"2025-02-27 07:43","pubTimestamp":1740613383,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLXDE4177:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2514074535","title":"ASX Growth Companies With High Insider Ownership For February 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514074535","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514074535?lang=en_us&edition=fundamental","pubTime":"2025-02-26 12:02","pubTimestamp":1740542556,"startTime":"0","endTime":"0","summary":"As the ASX 200 experiences a slight dip, influenced by persistent underlying inflation and cautious market sentiment, investors are closely monitoring sectors like Energy and Industrials which have shown resilience. In this fluctuating environment, growth companies with high insider ownership can offer unique insights into potential stability and alignment of interests between management and shareholders.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 101 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Operations: The company's revenue primarily comes from its mine operations, generating A$366.04 million.Operations: The company's revenue segment consists of A$413.26 million generated from its quick service restaurant operations across multiple international markets.Guzman y Gomez demonstrates promising growth with substantial insider ownership, evidenced by its recent inclusion in the S&P Global BMI In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-companies-high-insider-040236338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NWF.AU","BK7104","AAL.AU","EMR.AU","CUV.AU","BK7508","BK7084","3DP.AU","XAO.AU","BK7093","FND.AU","BK7067","MIN.AU","BK7016","XKO.AU","BK7077","XJO.AU","BK7095","BK7116","BK7043","GYG.AU","PLT.AU","BK7507","BK7504","MM8.AU","BK7137","BK7096","BK7158","AVA.AU","GTI.AU","ACR.AU"],"gpt_icon":0},{"id":"2513923407","title":"3 ASX Growth Stocks With High Insider Ownership To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2513923407","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513923407?lang=en_us&edition=fundamental","pubTime":"2025-02-24 12:02","pubTimestamp":1740369763,"startTime":"0","endTime":"0","summary":"As the Australian market braces for a potential downturn, with ASX 200 futures indicating a significant decline following Wall Street's recent struggles, investors are keenly watching how local companies navigate these turbulent times. In such an environment, growth stocks with high insider ownership can be particularly appealing, as they often signal confidence from those closest to the company's operations and strategy.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 99 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Overview: MA Financial Group Limited, with a market cap of A$1.33 billion, operates in Australia offering a range of financial services through its subsidiaries.Operations: MA Financial Group Limited generates revenue through its subsidiaries by providing a variety of financial services within Australia.MA Financial Group is poised for significant earnings growth, with forecasts indicatin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-growth-stocks-high-040243085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","LU0109392836.USD","LU1623119135.USD","LU0823421333.USD","AVA.AU","LU2063271972.USD","BK7067","SG9999001424.SGD","LU0964807845.USD","LU0094547139.USD","ACR.AU","IE00BYQQ9H92.USD","LU1551013342.USD","SKS.AU","LU0689472784.USD","MM8.AU","XKO.AU","XJO.AU","3DP.AU","XAO.AU","LU0942090050.USD","IE0004091025.USD","LU2756315318.SGD","LU2720916845.USD","LU0417517546.SGD","IE0009356076.USD","LU1551013425.SGD","IE00BJJMRX11.SGD","BK4106","EMR.AU","NWF.AU","CUV.AU","LU1917777945.USD","LU0820562030.AUD","LU0823421416.USD","MA","LU0786609619.USD","FLT.AU","LU0107464264.USD","BK7043","BK7508","MAF.AU","LU1712237335.SGD","LU0234572021.USD","IE00B775H168.HKD","BK7104","LU0106261372.USD","FND.AU","UNI.AU","PLT.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-06","defaultRemindTime":1725494400000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-20","payableDate":"2024-09-06","currency":"AUD","dateTimestamp":1725458400000,"payDate":"2024-09-20"},{"date":"2024-08-29","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724889600000,"name":null,"time":"","dateTimestamp":1724853600000,"actualEps":null},{"date":"2024-02-22","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":"2023-08-29","type":"dividend","market":"AU","newRecordDate":"2023-09-06","defaultRemindTime":1693872000000,"name":"Clinuvel Pharmaceuticals Ltd","recordDate":"2023-09-20","payableDate":"2023-09-06","currency":"AUD","dateTimestamp":1693836000000,"payDate":"2023-09-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}]}}